No abstract available
Publication types
-
Clinical Trial, Phase III
-
Letter
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antibodies, Bispecific / adverse effects
-
Antibodies, Bispecific / therapeutic use*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Humans
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Recurrence, Local / genetics
-
Philadelphia Chromosome* / drug effects
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
-
Treatment Outcome
Substances
-
Antibodies, Bispecific
-
Antineoplastic Agents
-
blinatumomab
Associated data
-
ClinicalTrials.gov/NCT02013167